Fudan-Zhangjiang(SH:688505)2025-02-27 11:15Financial Performance - Total revenue for 2024 was RMB 709.40 million, a decrease of 16.61% compared to RMB 850.73 million in the previous year[4] - Operating profit fell to RMB 2.39 million, down 97.53% from RMB 97.09 million year-on-year[4] - Net profit attributable to shareholders was RMB 39.73 million, a decline of 63.42% from RMB 108.63 million in the previous year[4] - Basic earnings per share decreased to RMB 0.04, down 63.64% from RMB 0.11 in the previous year[4] Research and Development - R&D expenses increased significantly, with an additional RMB 70 million compared to the previous year, driven by the advancement of multiple R&D projects[6] - The FDA018 antibody-drug conjugate project entered Phase III clinical trials, with over 40 clinical trial centers initiated[5] - The FZ-AD005 antibody-drug conjugate project entered Phase I clinical trials, with the first patient enrolled in July 2024[5] Assets and Equity - The company’s total assets decreased by 10.09% to RMB 2.59 billion from RMB 2.88 billion at the beginning of the reporting period[4] - The company’s equity attributable to shareholders decreased by 2.25% to RMB 2.30 billion from RMB 2.36 billion at the beginning of the reporting period[4] Sales and Revenue Impact - The company’s main product sales declined due to the termination of cooperation with a promotional service provider, impacting overall revenue[5]